First Gene Therapy for Pediatric Leukemia

FDA Approves First Gene Therapy for Pediatric Leukemia
Acute Myeloid LeukemiaPediatric Cancers
The US Food and Drug Administration (FDA) has approved the first gene therapy available in the United States, tisagenlecleucel (Kymriah; Novartis), for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy, which uses a patient’s own immune cells to target their cancer.
Specifically, tisagenlecleucel targets CD19-positive ALL. Patients undergoing treatment with tisagenlecleucel have T cells collected and sent to a manufacturer where they are genetically modified with a receptor to target CD19 on the surface of the cancer cells. Once the cells are modified, they are infused back into the patients to kill cancer cells.
The treatment has been approved for patients aged up to 25 years.
“Mariah is a first-of-its-kind treatment approach that fills an important unmet need for children and young adults with this serious disease,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research. “Not only does Kymriah provide these patients with a new treatment option were very limited options existed, but a treatment option that has shown promising remission and survival rates in clinical trials.”
The approval was based on a multicenter trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor ALL. Within 3 months of treatment with tisagenlecleucel, the overall remission rate was 83%.
Treatment with tisagenlecleucel was associated with some severe side effects in the trial. Therefore, tisagenlecleucel carries a boxed warning for cytokine release syndrome (CRS), a systemic response to activation and proliferation of CAR T cells that causes high fever and flu-like symptoms. In response, the FDA also expanded the approval of tocilizumab (Actemra; Genentech) to treat severe or life-threatening CAR T-cell–induced CRS in patients aged 2 years or older. This label expansion was based on clinical trial results that showed that 69% of patients had complete resolution of CRS within 2 weeks of 1 or 2 doses of tocilizumab.
“The approval of CAR T-cell therapy for pediatric leukaemia marks an important shift in the blood cancer treatment paradigm,” said Kenneth C. Anderson, MD, American Society of Hematology President, of the Dana-Farber Cancer Institute in Boston, in a prepared statement. “We now have proof that it is possible to eradicate cancer by harnessing the power of a patient’s own immune system. This is a potentially curative therapy in patients whose leukaemia is unresponsive to other treatments and represents the latest milestone in the shift away from chemotherapy toward precision medicine.”
“While the importance of CAR T-cell therapy cannot be overstated, this approval only pertains to a small population of children,” Anderson said. “More research is needed to make this therapy more effective for a broader population, to reduce the severe side effects that patients experience during treatment, and ultimately to find a broader application beyond blood cancers.”
Tisagenlecleucel has been approved with a risk evaluation and mitigation strategy, requiring hospitals and associated clinics that dispense the drug to be specially certified. Staff involved in the prescribing, dispensing, or administering of tisagenlecleucel must be trained to recognize and manage CRS and neurologic events.


Comments

Post a Comment

Popular posts from this blog

Breast cancer charities: How to make an impact

Breast cancer charities: How to make an impact With thousands of charities competing for donations, it can be difficult to know where a financial gift to a good cause will make the biggest impact. This article outlines the top  breast cancer  charities in the United States and their specific contributions to the cause, plus other factors to keep in mind before donating. The history of the pink ribbon The pink ribbon is a symbol of breast cancer and is often sold to raise money for breast cancer charities. Breast cancer activist and survivor Charlotte Hayley inspired the design of the pink ribbon, which is still in use today. Hayley initially handed out peach-coloured looped ribbons that she made herself with a card stating: "The National Cancer Institute's annual budget is $1.8 billion, only 5 percent goes for  cancer  prevention. Help us wake up our legislators and America by wearing this ribbon." In 1991, the Susan G. Komen Breast Cancer Foundati...
Read more

Lung cancer and cough: What is the connection?

Image
Lung cancer and cough: What is the connection? Everyone has experienced a nagging cough after a cold or needed to cough while in a quiet room. Despite these problems, coughing actually serves a very valuable and useful purpose. Coughing is a protective action, helping the lungs clear out potential germs or harmful objects.  Sometimes, however, that cough is not linked to a cold or infection and can linger for weeks to months at a time. This may lead people to wonder or worry that their cough is a sign of something more serious, such as  lung cancer . This article takes a look at the connection between coughing and lung cancer, including when someone should see a doctor. Coughing and lung cancer A cough associated with lung cancer may be either dry or wet. Not every a cough signifies the presence of lung cancer. However, many people do complain of a chronic cough or a "cough that just won't go away" at the time of their diagnosis. If a cough is associate...
Read more

For people with Type 2 diabetes, there is an additional incentive for keeping the disease under management

For people with Type 2 diabetes, there is an additional incentive for keeping the disease under management  Research shows a possible link between diabetes and cognitive decline, including increased risk for Alzheimer’s disease and vascular dementia. The scientific reason behind the link between diabetes and brain health is complex. Some scientists believe people with diabetes may also have insulin resistance or insulin deficiency that could damage brain cells enough to cause memory loss. Studies are underway to understand why 80 percent of people with Alzheimer’s disease also have some form of diabetes or disturbed glucose metabolism. However, so far, longitudinal research has not produced a consensus view regarding the link between blood glucose levels and cognitive impairment. Meanwhile, in South Florida, medical professionals are working with diabetic patients to minimize the risk of cognitive decline through a variety of methods that include lifestyle, medical and mental-...
Read more